Panbela Therapeutics Inc. (PBLA)
(Delayed Data from OTC)
$0.34 USD
-0.01 (-2.16%)
Updated Sep 20, 2024 11:57 AM ET
3-Hold of 5 3
F Value A Growth F Momentum D VGM
Balance Sheet
Fiscal Year End for Panbela Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 3 | 1 | 12 | 9 | 2 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 |
Total Current Assets | 3 | 2 | 12 | 10 | 3 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 9 | 3 | 1 | 0 | 0 |
Total Assets | 12 | 5 | 13 | 10 | 3 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 1 | 0 | 0 | 1 |
Accounts Payable | 10 | 3 | 1 | 1 | 1 |
Current Portion Long-Term Debt | 1 | 1 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 1 | 3 | 2 | 1 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 12 | 8 | 3 | 1 | 2 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 4 | 5 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 17 | 13 | 3 | 1 | 2 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 120 | 82 | 66 | 55 | 42 |
Retained Earnings | -126 | -91 | -56 | -46 | -41 |
Other Equity | 1 | 1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -5 | -8 | 10 | 8 | 1 |
Total Liabilities & Shareholder's Equity | 12 | 5 | 13 | 10 | 3 |
Total Common Equity | -5 | -8 | 10 | 8 | 1 |
Shares Outstanding | 0.20 | 0.00 | 0.00 | 0.00 | NA |
Book Value Per Share | -23.55 | -8.05 | 10.21 | 8.45 | 0.00 |
Fiscal Year End for Panbela Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 0 | 0 | 3 | 1 | 7 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 1 | 0 | 1 | 3 |
Total Current Assets | 1 | 2 | 3 | 2 | 11 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 9 | 9 | 9 | 9 | 9 |
Total Assets | 9 | 11 | 12 | 11 | 20 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 14 | 9 | 10 | 7 | 8 |
Current Portion Long-Term Debt | 1 | 1 | 1 | 1 | 1 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 1 | 1 | 1 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 17 | 11 | 12 | 9 | 11 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 3 | 3 | 4 | 4 | 4 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 20 | 14 | 17 | 13 | 15 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 128 | 128 | 120 | 106 | 106 |
Retained Earnings | -140 | -133 | -126 | -110 | -102 |
Other Equity | 1 | 1 | 1 | 1 | 1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -11 | -3 | -5 | -2 | 5 |
Total Liabilities & Shareholder's Equity | 9 | 11 | 12 | 11 | 20 |
Total Common Equity | -11 | -3 | -5 | -2 | 5 |
Shares Outstanding | 3.40 | 3.40 | 0.20 | 0.10 | 0.10 |
Book Value Per Share | -3.11 | -0.94 | -23.55 | -24.80 | 48.00 |